265 related articles for article (PubMed ID: 30043566)
1. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
2. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
3. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
4. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
5. Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Cao J; Lv W; Wang L; Xu J; Yuan P; Huang S; He Z; Hu J
Cell Death Dis; 2018 Jul; 9(8):817. PubMed ID: 30050135
[TBL] [Abstract][Full Text] [Related]
6. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-κB pathway.
Zhang WB; Zhang HY; Jiao FZ; Wang LW; Zhang H; Gong ZJ
Biomed Pharmacother; 2018 Jan; 97():818-824. PubMed ID: 29112935
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Amengual JE; Prabhu SA; Lombardo M; Zullo K; Johannet PM; Gonzalez Y; Scotto L; Serrano XJ; Wei Y; Duong J; Nandakumar R; Cremers S; Verma A; Elemento O; O'Connor OA
Clin Cancer Res; 2017 Jun; 23(12):3084-3096. PubMed ID: 27993968
[No Abstract] [Full Text] [Related]
9. Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
Vekaria PH; Kumar A; Subramaniam D; Dunavin N; Vallurupalli A; Schoenen F; Ganguly S; Anant S; McGuirk JP; Jensen RA; Rao R
Leukemia; 2019 Jul; 33(7):1675-1686. PubMed ID: 30664664
[TBL] [Abstract][Full Text] [Related]
10. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
Amengual JE; Johannet P; Lombardo M; Zullo K; Hoehn D; Bhagat G; Scotto L; Jirau-Serrano X; Radeski D; Heinen J; Jiang H; Cremers S; Zhang Y; Jones S; O'Connor OA
Clin Cancer Res; 2015 Oct; 21(20):4663-75. PubMed ID: 26116270
[TBL] [Abstract][Full Text] [Related]
12. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Lee DH; Kim GW; Kwon SH
Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983
[TBL] [Abstract][Full Text] [Related]
13. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
Benoy V; Vanden Berghe P; Jarpe M; Van Damme P; Robberecht W; Van Den Bosch L
Neurotherapeutics; 2017 Apr; 14(2):417-428. PubMed ID: 27957719
[TBL] [Abstract][Full Text] [Related]
14. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ; Almeciga-Pinto I; Tamang D; Yang M; Jones SS; Quayle SN
PLoS One; 2017; 12(3):e0173507. PubMed ID: 28264055
[TBL] [Abstract][Full Text] [Related]
16. Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.
Wu CP; Hsieh YJ; Murakami M; Vahedi S; Hsiao SH; Yeh N; Chou AW; Li YQ; Wu YS; Yu JS; Ambudkar SV
Biochem Pharmacol; 2018 Sep; 155():316-325. PubMed ID: 30028995
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy.
Chen X; Yu C; Hou X; Li J; Li T; Qiu A; Liu N; Zhuang S
Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1003-F1014. PubMed ID: 33103445
[TBL] [Abstract][Full Text] [Related]
18. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy.
Park SJ; Joo SH; Lee N; Jang WJ; Seo JH; Jeong CH
Arch Pharm Res; 2021 Dec; 44(12):1062-1075. PubMed ID: 34761352
[TBL] [Abstract][Full Text] [Related]
19. HDAC6 inhibitor ACY-1215 improves neuropathic pain and its comorbidities in rats of peripheral nerve injury by regulating neuroinflammation.
Chen C; Liu A; Lu Q; Luo L; Li J; Ke J; Liu Y; Feng X
Chem Biol Interact; 2022 Feb; 353():109803. PubMed ID: 34998817
[TBL] [Abstract][Full Text] [Related]
20. HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Sakloth F; Manouras L; Avrampou K; Mitsi V; Serafini RA; Pryce KD; Cogliani V; Berton O; Jarpe M; Zachariou V
Psychopharmacology (Berl); 2020 Jul; 237(7):2139-2149. PubMed ID: 32388618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
